Hannah Valantine

Director Hannah Valantine sold 28,779 shares (44.0% of holdings) at $36.14–$36.55 via pre-arranged 10b5-1 plan; retains 36,686 shares plus 24,011 stock options.

Hannah Valantine executed 2 separate sales totaling 28,779 shares for $1,040,243.12 at blended average price $36.15, reducing her non-derivative holdings from 65,465 to 36,686 shares. The transaction was part of a pre-arranged 10b5-1 trading plan adopted on 2025-12-11, making it scheduled rather than discretionary; therefore timing characterization does not apply. Her cross-ticker track record shows 3 prior sells with average 90-day post-sale return of +4.2%, indicating her prior sales preceded modest forward appreciation. The company reported positive quarterly revenue of $117,700,000.00 and quarterly net income of $2,809,000.00, though it was unprofitable on a full-year basis. Current stock price of $39.73 is -1.8% from the 52-week high of $40.47, while the 30-day change was +69.2% and 90-day change was +85.5%. Valantine retains meaningful ownership: 36,686 non-derivative shares plus 24,011 stock options (Right to Buy) in derivative form.

Director Valantine Hannah sells 25,484 shares of BBIO for $1,717,780.84 under pre-arranged 10b5-1 plan

Director Valantine Hannah executed 2 separate sales totaling 25,484 shares for $1,717,780.84 at a blended average price of $67.41 on 2026-02-27. This sale reduced her holdings by 77.3% from 32,949 shares to 7,465 shares post-transaction. The transaction was conducted pursuant to a 10b5-1 trading plan adopted on 2025-11-14, meaning it was scheduled in advance rather than discretionary. Because this sale is part of a pre-arranged plan, it reflects execution of a planned divestiture schedule rather than a real-time market decision. Investors should note the substantial reduction in her stake, though the scheduled nature of the plan limits what can be inferred about current conviction or market timing.

Director Valantine Hannah sold 25,484 shares of BBIO at $66.07 on 2025-11-12, reducing stake by 77.3% to 7,465 shares ($1.7M value).

Valantine Hannah, a director of BridgeBio Pharma, executed a substantial sale of 25,484 shares (77.3% reduction in holdings) at $66.07, leaving a minimal remaining position of 7,465 shares. The company is unprofitable with negative net income of $-184,937,000.00 in its most recent full fiscal year, despite strong revenue growth of 2285.3% year-over-year and recent quarterly revenue of $120,700,000.00. The transaction occurred near the 52-week high of $66.62 and followed a notable 30-day price increase of 17.2%, positioning this as a near-peak sale by a director who has substantially diminished insider holdings. The dramatic reduction in stake—from 32,949 to 7,465 shares—warrants investor scrutiny regarding the director's confidence in the company's trajectory, particularly given the persistent unprofitability despite accelerating revenue.